PMID

Data

Article Title

Organization

Irreversible inhibitors of cysteine proteases.

Dart Neuroscience

Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.

University of Florida

Identification of promiscuous small molecule activators in high-throughput enzyme activation screens.

University of Illinois

Exploiting differences in caspase-2 and -3 S2 subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.

Chdi Management

Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo.

University of Edinburgh

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.

Shionogi

Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.

Merck Frosst Centre For Therapeutic Research

Discovery of a Series of Pyrimidine Carboxamides as Inhibitors of Vanin-1.

Pfizer

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.

Pfizer

Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.

Roche Pharma Research and Early Development

Selective caspase inhibitors and uses thereof

Novagenesis Foundation

Potent and selective nonpeptide inhibitors of caspases 3 and 7.

Glaxosmithkline

Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.

Shanghai Institutes For Biological Sciences

Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design.

Sunesis Pharmaceuticals